Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 03 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

This medication is indicated for treating Refractory Complex Partial Seizures and infantile spasms in young patients. The drug will be manufactured at Zydus's facility in Moraiya, Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 03, 2023, titled "Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution USP, 500 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases